SecBot SecBot

ACRV drug pipeline

$1.46
+0.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.2%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2b (registrational-intent)
Time to marketUnknown — no approval filing or PDUFA is scheduled. If the Phase 2b interim is positive, an FDA submission would still be a later, undated step; realistic commercialization would be several years out.

ACR-368 Updated Aug 21

What to watch

The stock is a pure binary bet on the 2H 2026 Phase 2b interim readout in serous endometrial cancer, a positive result could drive a large move toward the $11.50 mean analyst target (implied upside ~377% from the $2.20 close), while a miss would likely be severe for a company whose cash only runs into Q2 2027. Watch company guidance for a firm interim date, and treat the 52% cORR maturing data and Fast Track designation as encouraging but not de-risked; note the Breakthrough designation was for the OncoSignature diagnostic assay, not the drug itself.

Bull case
  • Maturing Phase 2b data showed a 52% confirmed overall response rate (cORR) in serous endometrial cancer, reported with Q4/FY2025 results (8-K filed 2026-03-19; press release sentiment rated bullish, impact 8).
  • FDA granted Fast Track designation for ACR-368 as a monotherapy in endometrial cancer, and Breakthrough Device designation for the ACR-368 OncoSignature assay (FDA-catalyst extraction dated 2026-03-19).
  • The registrational-intent Phase 2b prespecified interim analysis plus all-comer (biopsy-independent) serous EC arm data is on track for 2H 2026, reaffirmed at the Aug 12, 2026 Q2 earnings update, a defined near-term catalyst.
Bear case
  • The 2H 2026 Phase 2b interim is a make-or-break binary on a micro-cap: the stock closed ~$2.20 (52-week range $1.27–$3.56), so a negative interim would hit equity value hard, with cash only funding operations into Q2 2027.
  • Elevated bearish flow signals: SecBot's 90-day checklist flags a weighted short-volume ratio of ~0.475 over 51 sessions (FINRA daily short-sale flow, not short interest), plus multiple institutional trims/near-exits in recent 13F quarters.
  • FINRA semi-monthly short interest of 1,355,015 shares (~3.17% of ESTIMATED shares outstanding, days-to-cover 4.30) as of the 2026-07-31 settlement.
● neutral
Impact
PhaseEarly clinical (Phase 1-type); no Phase 2/3 trial yet
Time to marketUnknown — likely several years away: the drug is in early clinical (Phase 1-type) testing as of mid-2026, with no registrational trial started.

ACR-2316 Updated Aug 21

What to watch

ACR-2316 is a longer-dated option inside Acrivon: watch for quantitative response/tolerability numbers from its ongoing Phase 1 dose escalation at oncology congresses, since the July 2026 AACR D3 disclosure contained no patient counts or response rates. Note that near-term ACRV share-price action is driven by the ACR-368 Phase 2b prespecified interim analysis and all-comer serous endometrial cancer data guided for 2H 2026, not by ACR-2316, so any trade thesis should center on ACR-368 with ACR-2316 as upside optionality.

Bull case
  • Potential first-in-class dual WEE1/PKMYT1 inhibitor, rationally designed with Acrivon's AP3 platform for potent single-agent activity and a 'superior therapeutic index' (July 21, 2026 AACR D3 release).
  • Early clinical data show partial responses across multiple AP3-predicted tumor types with a favorable tolerability profile, plus 'initial clinical activity' in lung cancer per the Q4/FY2025 results release (March 19, 2026).
  • Preclinical data (AACR, April 17, 2026) show strong synergy of ACR-2316 with immune checkpoint inhibitors (anti-PD-L1), suggesting broad combination development optionality.
Bear case
  • Very early stage: the July 2026 AACR D3 disclosure gave no quantitative response rates or patient numbers, so the clinical signal is unproven and Phase 1 data frequently fails to replicate in later trials.
  • No scheduled hard catalyst for ACR-2316 in the next ~12 months; ACRV's dated near-term event is the ACR-368 Phase 2b interim analysis in 2H 2026 (Aug 12, 2026 release), so this drug alone won't drive a major move.
  • Crowded and competitive WEE1 space: Zentalis' azenosertib is late-stage and just raised ~$92.6M gross (Aug 2026), and Aprea's WEE1 inhibitor APR-1051 is in Phase 1 with partial responses reported, first-in-class is not the same as only-in-class.
● neutral
Impact
PhasePhase 2-ready (Phase 1 completed)
Time to marketACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).

ACR-525 Updated Nov 9

What to watch

Watch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.

Bull case
  • ACR-525 is a Phase 2-ready, oral, highly selective JAK1 inhibitor with a formulation designed for EoE patients who have difficulty swallowing, a clear differentiator.
  • Acrivon's AP3 platform profiling characterized ACR-525 as having minimal off-target effects compared to approved JAK inhibitors and dupilumab.
  • The deal includes no future milestone or royalty obligations, giving Acrivon full downstream upside if the drug succeeds.
Bear case
  • Undisclosed acquisition cost creates uncertainty about cash burn and potential dilution for a ~$75M market cap company.
  • ACR-525 is Phase 2-ready but has not yet demonstrated efficacy in EoE or any indication; clinical risk remains high.
  • Acrivon is primarily an oncology company; the pivot into immunology/inflammation requires new expertise and resource allocation away from its core pipeline.

Other drugs in filings and trials

no drug report yet
  • ACR-6840 Last: NDA filed · Oct 1, 2026

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Oct 1, 2026ACR-6840NDA filed−2.9%−8.8%
Mar 19, 2026ACR-368Breakthrough designation+1.2%−13.4%
Mar 19, 2026ACR-368Fast Track+1.2%−13.4%